PCSK9: A new participant in lipophagy in regulating atherosclerosis?

被引：10
作者：
Xiao, Jun [1 ]
Deng, Yi-Min [1 ]
Liu, Xiang-Rui [1 ]
Cao, Jian-Ping [2 ]
Zhou, Min [1 ]
Tang, Ya-Ling [1 ]
Xiong, Wen-Hao [1 ]
Jiang, Zhi-Sheng [1 ]
Tang, Zhi-Han [1 ]
Liu, Lu-Shan [1 ]
机构：
[1] Univ South China, Hunan Int Sci & Technol Cooperat Base Arterioscle, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China
[2] Hunan Environm Biol Vocat & Tech Coll, Hengyang 421001, Hunan, Peoples R China
来源：
CLINICA CHIMICA ACTA | 2019年 / 495卷
基金：
中国国家自然科学基金;
关键词：
Proprotein convertase subtilisin kexin 9; Lipophagy; Lipid metabolism; Low density lipoprotein receptor; Atherosclerosis; SUBTILISIN/KEXIN TYPE 9; LIPID DROPLETS; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION; APOLIPOPROTEIN-B; RAB7; EFFECTOR; LIVER-DISEASE; AUTOPHAGY; PROTEIN; DEGRADATION;
D O I：
10.1016/j.cca.2019.05.005
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis.
引用
收藏
页码：358 / 364
页数：7
相关论文
共 50 条
  • [21] Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes
    Heena Agarwal
    Brea Tinsley
    Amesh K. Sarecha
    Lale Ozcan
    Current Atherosclerosis Reports, 2023, 25 : 931 - 937
  • [22] Back to Basics: PCSK9 as a New Target for the LDL Receptor
    Corral, Pablo
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2014, 102 (01) : E5 - E8
  • [23] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke
    Zhang, Lingling
    Song, Kangping
    Zhu, Mengting
    Shi, Jinling
    Zhang, Huijuan
    Xu, Liang
    Chen, Yingzhu
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (08) : 675 - 680
  • [24] PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?
    Bai, Xue-qin
    Peng, Juan
    Wang, Mei-mei
    Xiao, Jun
    Xiang, Qiong
    Ren, Zhong
    Wen, Hong-yan
    Jiang, Zhi-sheng
    Tang, Zhi-han
    Liu, Lu-shan
    CLINICA CHIMICA ACTA, 2018, 483 : 192 - 196
  • [25] PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation
    Toth, Stefan
    Olexa, Peter
    Hertelyova, Zdenka
    Stefanic, Peter
    Kopolovets, Ivan
    Berek, Peter
    Filip, Vladimir
    Chakravarty, Ryan
    Siroka, Monika
    Pella, Daniel
    OPEN CHEMISTRY, 2020, 18 (01): : 1011 - 1019
  • [26] Targeting PCSK9 for Therapeutic Gains
    Shapiro, Michael D.
    Fazio, Sergio
    Tavori, Hagai
    CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (04)
  • [27] Inhibition of PCSK9 in familial hypercholesterolaemia
    Sijbrands, Eric J. G.
    LANCET, 2012, 380 (9836) : 6 - 7
  • [28] CRISPR-Cas9 Targeting PCSK9: A Promising Therapeutic Approach for Atherosclerosis
    Gu, Bin
    Li, Min
    Li, Dan
    Huang, Kaisen
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2025, : 424 - 441
  • [29] PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
    Lagace, Thomas A.
    CURRENT OPINION IN LIPIDOLOGY, 2014, 25 (05) : 387 - 393
  • [30] Beyond LDL Cholesterol, a New Role for PCSK9
    Akram, Omar N.
    Bernier, Adeline
    Petrides, Francine
    Wong, Gida
    Lambert, Gilles
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (07) : 1279 - 1281
12345